Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » Data from Combination Studies | ASCO 2019 Will Show The Role of New Combinations

Multiple Myeloma

Data from Combination Studies | ASCO 2019 Will Show The Role of New Combinations

By EditorAugust 23, 2018No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

John P. Fruehauf, MD, UC Irvine Health, Looks at Data from Combination Studies | ASCO 2019 Will Show The Role of New Combinations at MOASC 2018

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024

ASCO Annual Meeting 2 Mins Read

Linvoseltamab: A Groundbreaking Advance in Multiple Myeloma Treatment

Multiple Myeloma 4 Mins Read

Spotlight on Myeloma 2024: Innovations and Insights from ASH

Multiple Myeloma 3 Mins Read

Advertisement Sidebar

Recent Posts

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
Metastatic Breast Cancer: Trastuzumab (Herceptin) Factors for Long-Term Remission in HER2 negative
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Connect With Us on Social

Facebook
Twitter
LinkedIn

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.